Overview

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated before.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Bevacizumab
Fluorouracil
Oxaliplatin
Sunitinib